Verastem (VSTM) Cash & Equivalents (2011 - 2026)

Verastem's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $181.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 54.55% year-over-year to $181.7 million; the TTM figure through Mar 2026 stood at $181.7 million (up 54.55% YoY), while the FY2025 annual figure was $205.0 million, up 130.8% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $181.7 million, down from $205.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $205.0 million in Q4 2025, with the low at $46.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $95.0 million (2023), against an average of $111.4 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 221.49% in 2022, then sank 54.46% in 2024.
• Verastem's Cash & Equivalents stood at $79.1 million in 2022, then retreated by 1.48% to $77.9 million in 2023, then advanced by 14.0% to $88.8 million in 2024, then surged by 130.8% to $205.0 million in 2025, then slipped by 11.36% to $181.7 million in 2026.
• Business Quant data shows VSTM's Cash & Equivalents at $181.7 million in Q1 2026, $205.0 million in Q4 2025, and $137.7 million in Q3 2025.